For example, the study by Song et al. (2022) builds on this paradigm by designing a dual-immunomodulator albumin nanoparticle, Nano-PI, containing PI3Kγ inhibitor (IPI-549) and paclitaxel (PTX).157 This innovative approach addresses the immunosuppressive tumor microenvironment (TME) that hinders the efficacy of current immunotherapies, such as α-PD1 or α-PDL1, particularly in triple-negative breast cancer (TNBC). This evidence concerns the gene ALB and neoplasm.